Calvin Ivy Masse, | |
1000 Mount Olivet Rd Ne, Washington, DC 20002-2210 | |
(202) 440-2925 | |
Not Available |
Full Name | Calvin Ivy Masse |
---|---|
Gender | Male |
Speciality | Home Health Aide |
Location | 1000 Mount Olivet Rd Ne, Washington, District Of Columbia |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1134740996 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
103TC1900X | Psychologist - Counseling | (* (Not Available)) | Secondary |
374U00000X | Home Health Aide | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Calvin Ivy Masse, 13217 Stravinsky Dr, Silver Spring, MD 20904-6838 Ph: (443) 653-0250 | Calvin Ivy Masse, 1000 Mount Olivet Rd Ne, Washington, DC 20002-2210 Ph: (202) 440-2925 |
News Archive
Lower-income patients want to communicate electronically with their doctors, but the revolution in health care technology often is not accessible to them, due to inadequate health information services within the health care clinics they frequent, according to a survey by UC San Francisco researchers.
Scientists at Vanderbilt and Yale universities have successfully transplanted most of the "nose" of the mosquito that spreads malaria into frog eggs and fruit flies and are employing these surrogates to combat the spread of the deadly and debilitating disease that afflicts 500 million people.
Functional profiling using ex-vivo analysis of programmed cell death (EVA/PCD) doubles the response rate and improves time-to-progression and survival in patients with advanced lung cancer, according to a Phase II clinical trial conducted by investigators at Rational Therapeutics and the MemorialCare Todd Cancer Institute and published in the October issue of Anticancer Research.
Results from the VeriStrat biomarker analysis of a multicenter Phase III trial were presented today at the 2nd European Lung Cancer Conference currently being held in Geneva, Switzerland. Results showed that the VeriStrat test identified patients who were likely to have a survival benefit from treatment with erlotinib, a commonly prescribed oral therapy for advanced non-small cell lung cancer.
› Verified 3 days ago